Latest On Harpoon Therapeutics, Inc (HARP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 20:27 EST | News | Harpoon Therapeutics GAAP EPS of -$0.31 beats by $0.08, revenue of $8.58M beats by $3.77M | N/A |  |
| 2023-04-21 21:04 EST | News | Harpoon Therapeutics files $250M mixed shelf registration | N/A | |
| 2023-03-28 07:03 EST | News | Harpoon Therapeutics GAAP EPS of -$0.55 misses by $0.08, revenue of $4.1M misses by $2.94M | N/A | |
| 2023-02-27 15:22 EST | News | Harpoon Therapeutics (HARP) Presents at SVB Securities Global Biopharma Conference 2023 | N/A | |
| 2022-12-12 14:19 EST | News | Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy | N/A | |
| 2022-11-15 19:48 EST | News | Harpoon Therapeutics GAAP EPS of -$0.35 beats by $0.20, revenue of $13.6M beats by $7.25M | N/A | |
| 2022-10-04 17:03 EST | News | Harpoon Therapeutics appoints Luke Walker as CMO | N/A | |
| 2022-10-04 17:02 EST | News | AstraZeneca – LogicBio deal indicates more such takeovers are ahead – Cantor | N/A | |
| 2022-09-01 06:10 EST | News | Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player | N/A | |
| 2022-08-10 17:36 EST | News | Harpoon Therapeutics GAAP EPS of -$0.53 beats by $0.03, revenue of $8.3M beats by $1.34M | N/A | |
| 2022-07-08 04:35 EST | News | Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio | N/A | |
| 2022-05-16 12:57 EST | News | Harpoon stock soars 26% on Wedbush upgrade ahead of HPN328 data in lung cancer at ASCO | N/A | |
| 2022-05-12 18:12 EST | News | Harpoon Therapeutics GAAP EPS of -$0.62 misses by $0.07, revenue of $5.91M misses by $2.17M | N/A | |
| 2022-05-02 20:58 EST | News | Roche and Harpoon strike clinical supply agreement for cancer therapy | N/A | |
| 2022-04-08 00:28 EST | News | Harpoon Therapeutics falls as medical chief exits | N/A | |
| 2022-03-15 04:13 EST | News | Street firms cut price targets on Harpoon Therapeutics, but maintain buy ratings | N/A | |
| 2022-03-12 06:41 EST | News | Harpoon crashes on plans to halt prostate cancer study | N/A | |
| 2022-03-11 12:00 EST | News | Harpoon Therapeutics GAAP EPS of -$0.66 misses by $0.23, revenue of $4.3M misses by $1.9M | N/A | |
| 2022-03-07 20:36 EST | News | Harpoon Therapeutics wins FDA’s Orphan Drug Designation for lung cancer therapy | N/A | |
| 2022-03-02 18:07 EST | News | Harpoon wins FDA’s Fast Track designation for multiple myeloma therapy | N/A | |
| 2021-10-26 19:42 EST | News | Harpoon Therapeutics names board member Julie Eastland as new CEO | N/A | |
| 2021-09-28 17:31 EST | News | Harpoon Therapeutics, Puma Bio shares gain on Citi upgrade | N/A | |
| 2021-09-21 20:08 EST | News | Harpoon Therapeutics (HARP) Investor Presentation - Slideshow | N/A | |
| 2021-09-21 19:49 EST | News | Harpoon Therapeutics: A First Look | N/A | |
| 2021-08-06 04:04 EST | News | Harpoon Therapeutics EPS misses by $0.09, misses on revenue | N/A | |
| 2021-07-21 11:03 EST | News | Iterum keeps rising even as RBC analyst cautions, Premier hurt by Barclays’ double downgrade; and more in today’s analyst action | N/A | |
| 2021-07-21 10:58 EST | News | Harpoon shares slide after early-stage prostate cancer study data fails to impress | N/A | |
| 2021-07-21 10:58 EST | News | Merus upgraded on ASCO update, Cantor favors Harpoon after selloff; and more in today’s analyst action | N/A | |
| 2021-05-07 09:14 EST | News | Harpoon Therapeutics EPS misses by $1.50, beats on revenue | N/A | |
| 2021-03-31 02:30 EST | News | Harpoon Therapeutics: T-Cell Engager Platform For Immune-Related Disease | N/A | |
| 2021-03-12 11:44 EST | Analyst Rating | The Analyst Target Price has decreased from $31.67 to $31.22. | Neutral | |
| 2021-03-12 04:41 EST | News | Harpoon Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-03-11 19:55 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-11 11:44 EST | Earnings Estimate | An EPS average of -$0.53 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-11 11:44 EST | Earnings Estimate | An EPS average of -$2.17 is estimated for the 2022 year. | Sell | |
| 2021-03-11 11:44 EST | Analyst Rating | The Analyst Target Price has decreased from $31.89 to $31.67. | Neutral | |
| 2021-03-11 07:58 EST | News | Harpoon Therapeutics EPS beats by $0.11, beats on revenue | N/A | |
| 2021-03-11 07:58 EST | News | Harpoon Therapeutics, Inc. (HARP) CEO Gerald McMahon on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-01-13 14:24 EST | News | Harpoon Therapeutics' HPN217 an orphan drug in U.S. for multiple myeloma | N/A | |
| 2021-01-07 12:09 EST | News | Harpoon Therapeutics prices equity offering at $17 | N/A | |
| 2021-01-06 21:19 EST | News | Harpoon Therapeutics -2.6%, proposes public offering | N/A | |
| 2021-01-05 11:55 EST | Analyst Rating | The Analyst Target Price has increased from $31.56 to $31.89. | Buy | |
| 2021-01-04 10:22 EST | News | Dosing underway in Harpoon Therapeutics' HPN328 study in small cell lung cancer | N/A | |
| 2021-01-03 20:04 EST | News | Harpoon Therapeutics: Potential For Explosive Growth | N/A | |
| 2020-12-24 15:59 EST | Analyst Rating | The Analyst Target Price has increased from $31.22 to $31.56. | Buy | |
| 2020-12-09 01:02 EST | News | Harpoon Therapeutics reports partial response from HPN424 early-stage study in prostate cancer | N/A | |
| 2020-11-26 20:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 16:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-05 19:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-05 07:59 EST | Earnings Estimate | An EPS average of -$0.49 is estimated for the quarter ending on March 31, 2021. | Buy | |
About Harpoon Therapeutics, Inc (HARP):
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
General
- Name Harpoon Therapeutics, Inc
- Symbol HARP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 78
- Fiscal Year EndDecember
- IPO Date2019-02-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.harpoontx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 28.95
- Price/Book (Most Recent Quarter) 12.14
- Enterprise Value Revenue 31.02
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.95
- Next Year EPS Estimate -$2.04
- Next Quarter EPS Estimate -$0.54
- Profit Margin -286%
- Operating Margin -294%
- Return on Assets -18%
- Return on Equity -67%
- Revenue 17.44 million
- Earnings Per Share -$4.05
- Revenue Per Share $0.7
- Gross Profit -35121000
- Quarterly Earnings Growth 235.4%
View More
Highlights
- Market Capitalization 672.32 million
- EBITDA -42558000
- Analyst Target Price $31.22
- Book Value Per Share $2.11
View More
Share Statistics
- Shares Outstanding 32.41 million
- Shares Float 17.65 million
- % Held by Insiders 1109%
- % Held by Institutions 79.95%
- Shares Short 757801
- Shares Short Prior Month 678029
- Short Ratio 2.83
- Short % of Float 4%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 0.8
- 52 Week High $25.24
- 52 Week Low $10.27
- 50 Day Moving Average 19.49
- 200 Day Moving Average 17.2
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Harpoon Therapeutics, Inc (HARP) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Harpoon Therapeutics, Inc (HARP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-10 | $7.49 million | -$0.45 | -$0.53 | 14.5% |
| 2020-09-30 | 2020-11-04 | $N/A | -$0.53 | -$0.51 | -4.29% |
| 2020-06-30 | 2020-08-05 | $N/A | -$0.51 | -$0.47 | -8.72% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.51 | -$0.42 | -22.13% |
| 2019-12-31 | 2020-03-12 | $2.23 million | -$0.58 | -$0.55 | -6.31% |
| 2019-09-30 | 2019-11-06 | $1.42 million | -$0.65 | -$0.54 | -19.35% |
| 2019-06-30 | 2019-08-05 | $1.06 million | -$0.49 | -$0.63 | 21.6% |
| 2019-03-31 | 2019-05-09 | $1.06 million | -$0.56 | -$0.45 | -24.44% |
| 2018-12-31 | 2019-02-08 | $1.06 million | -$8.15 | -$0.72 | -1031.94% |
Harpoon Therapeutics, Inc (HARP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Harpoon Therapeutics, Inc (HARP) Chart:
Harpoon Therapeutics, Inc (HARP) News:
Below you will find a list of latest news for Harpoon Therapeutics, Inc (HARP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Harpoon Therapeutics, Inc (HARP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-21 | 12.5 | 0 | CALL | 0 | 0 | 162.12 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 126.66 | FALSE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | CALL | 0 | 0 | 96.81 | FALSE | 0 | 0 |
| 2024-06-21 | 20 | 0 | CALL | 0 | 0 | 70.22 | FALSE | 0 | 0 |
| 2024-06-21 | 22.5 | 0.55 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 25 | 0.05 | CALL | 0 | 247 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 30 | 0.05 | CALL | 0 | 12 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 20 | 0.1 | PUT | 0 | 61 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 22.5 | 0.05 | PUT | 0 | 89 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 30 | 0 | PUT | 0 | 0 | 35.02 | TRUE | 0 | 0 |
| 2024-09-20 | 12.5 | 0 | CALL | 0 | 0 | 118.46 | FALSE | 0 | 0 |
| 2024-09-20 | 15 | 0 | CALL | 0 | 0 | 92.02 | FALSE | 0 | 0 |
| 2024-09-20 | 17.5 | 0 | CALL | 0 | 0 | 69.89 | FALSE | 0 | 0 |
| 2024-09-20 | 20 | 0 | CALL | 0 | 0 | 50.35 | FALSE | 0 | 0 |
| 2024-09-20 | 22.5 | 0.55 | CALL | 0 | 45 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 25 | 0.05 | CALL | 0 | 115 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 30 | 3 | CALL | 0 | 50 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 12.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 15 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 17.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 20 | 0.1 | PUT | 0 | 195 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 22.5 | 0.05 | PUT | 0 | 142 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 25 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 30 | 0 | PUT | 0 | 0 | 29.5 | TRUE | 0 | 0 |
Latest HARP Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 10 | $2.05 |
| Jun 13, 2022 7:59 PM EST | 28 | $2.05 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.05 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.04 |
| Jun 13, 2022 7:59 PM EST | 20 | $2.05 |
Harpoon Therapeutics, Inc (HARP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120040695/0001209191-20-040695-index.htm |
| 2018-11-20 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1708493/000000000018035843/0000000000-18-035843-index.htm |
| 2019-02-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1708493/000000000019000638/0000000000-19-000638-index.htm |
| 2020-03-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1708493/000000000020002448/0000000000-20-002448-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000089924319002910/0000899243-19-002910-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000089924319003683/0000899243-19-003683-index.htm |
| 2019-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000089924319028848/0000899243-19-028848-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000089924319029473/0000899243-19-029473-index.htm |
| 2020-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000089924320014559/0000899243-20-014559-index.htm |
| 2019-02-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1708493/000094787119000133/0000947871-19-000133-index.htm |
| 2018-10-24 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1708493/000095012318010117/0000950123-18-010117-index.htm |
| 2018-12-12 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1708493/000095012318012342/0000950123-18-012342-index.htm |
| 2018-12-11 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1708493/000095012318012344/0000950123-18-012344-index.htm |
| 2018-12-27 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1708493/000119312518359160/0001193125-18-359160-index.htm |
| 2019-01-04 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1708493/000119312519002624/0001193125-19-002624-index.htm |
| 2019-01-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1708493/000119312519018441/0001193125-19-018441-index.htm |
| 2019-01-29 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1708493/000119312519019639/0001193125-19-019639-index.htm |
| 2019-02-04 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1708493/000119312519027138/0001193125-19-027138-index.htm |
| 2019-02-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1708493/000119312519027184/0001193125-19-027184-index.htm |
| 2019-02-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1708493/000119312519027885/0001193125-19-027885-index.htm |
| 2019-02-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1708493/000119312519027887/0001193125-19-027887-index.htm |
| 2019-02-05 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1708493/000119312519028374/0001193125-19-028374-index.htm |
| 2019-02-08 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1708493/000119312519032439/0001193125-19-032439-index.htm |
| 2019-02-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1708493/000119312519032459/0001193125-19-032459-index.htm |
| 2019-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312519038191/0001193125-19-038191-index.htm |
| 2019-02-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1708493/000119312519047013/0001193125-19-047013-index.htm |
| 2019-02-22 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1708493/000119312519048021/0001193125-19-048021-index.htm |
| 2019-02-22 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1708493/000119312519048049/0001193125-19-048049-index.htm |
| 2019-12-11 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1708493/000119312519311686/0001193125-19-311686-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1708493/000119312520033453/0001193125-20-033453-index.htm |
| 2020-03-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1708493/000119312520072999/0001193125-20-072999-index.htm |
| 2020-03-13 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1708493/000119312520073017/0001193125-20-073017-index.htm |
| 2020-03-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1708493/000119312520073069/0001193125-20-073069-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312520094749/0001193125-20-094749-index.htm |
| 2020-04-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312520098804/0001193125-20-098804-index.htm |
| 2020-04-17 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1708493/000119312520110768/0001193125-20-110768-index.htm |
| 2020-04-17 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1708493/000119312520110786/0001193125-20-110786-index.htm |
| 2020-04-17 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312520110801/0001193125-20-110801-index.htm |
| 2020-04-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1708493/000119312520113692/0001193125-20-113692-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312520155683/0001193125-20-155683-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312520157244/0001193125-20-157244-index.htm |
| 2020-06-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1708493/000119312520157363/0001193125-20-157363-index.htm |
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000119312520186045/0001193125-20-186045-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008203/0001209191-19-008203-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008208/0001209191-19-008208-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008210/0001209191-19-008210-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008215/0001209191-19-008215-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008229/0001209191-19-008229-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008239/0001209191-19-008239-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008246/0001209191-19-008246-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008253/0001209191-19-008253-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008256/0001209191-19-008256-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008259/0001209191-19-008259-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008260/0001209191-19-008260-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008264/0001209191-19-008264-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008265/0001209191-19-008265-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008266/0001209191-19-008266-index.htm |
| 2019-02-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119008270/0001209191-19-008270-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010288/0001209191-19-010288-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010297/0001209191-19-010297-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010303/0001209191-19-010303-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010306/0001209191-19-010306-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010312/0001209191-19-010312-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010317/0001209191-19-010317-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010320/0001209191-19-010320-index.htm |
| 2019-03-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119021729/0001209191-19-021729-index.htm |
| 2019-03-29 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119021730/0001209191-19-021730-index.htm |
| 2019-03-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119021731/0001209191-19-021731-index.htm |
| 2019-03-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119021736/0001209191-19-021736-index.htm |
| 2019-03-29 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119021745/0001209191-19-021745-index.htm |
| 2019-03-29 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119021751/0001209191-19-021751-index.htm |
| 2019-05-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119027964/0001209191-19-027964-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119028675/0001209191-19-028675-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119030200/0001209191-19-030200-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034828/0001209191-19-034828-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034836/0001209191-19-034836-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034841/0001209191-19-034841-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034842/0001209191-19-034842-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034844/0001209191-19-034844-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034847/0001209191-19-034847-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119034848/0001209191-19-034848-index.htm |
| 2019-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119048821/0001209191-19-048821-index.htm |
| 2019-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119053306/0001209191-19-053306-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119055169/0001209191-19-055169-index.htm |
| 2019-11-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119057167/0001209191-19-057167-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059085/0001209191-19-059085-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059489/0001209191-19-059489-index.htm |
| 2019-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059954/0001209191-19-059954-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061059/0001209191-19-061059-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061097/0001209191-19-061097-index.htm |
| 2019-12-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919119062169/0001209191-19-062169-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120002179/0001209191-20-002179-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120002180/0001209191-20-002180-index.htm |
| 2020-01-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120004374/0001209191-20-004374-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120004581/0001209191-20-004581-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120006700/0001209191-20-006700-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120006703/0001209191-20-006703-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120006706/0001209191-20-006706-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120006711/0001209191-20-006711-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120011190/0001209191-20-011190-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120015855/0001209191-20-015855-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120020052/0001209191-20-020052-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120022183/0001209191-20-022183-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120022188/0001209191-20-022188-index.htm |
| 2020-04-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120022193/0001209191-20-022193-index.htm |
| 2020-04-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120022196/0001209191-20-022196-index.htm |
| 2020-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120023954/0001209191-20-023954-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024489/0001209191-20-024489-index.htm |
| 2020-04-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024947/0001209191-20-024947-index.htm |
| 2020-04-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120026337/0001209191-20-026337-index.htm |
| 2020-05-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120027143/0001209191-20-027143-index.htm |
| 2020-05-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2020-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120029020/0001209191-20-029020-index.htm |
| 2020-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120031019/0001209191-20-031019-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033317/0001209191-20-033317-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033318/0001209191-20-033318-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033319/0001209191-20-033319-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033320/0001209191-20-033320-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033321/0001209191-20-033321-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033322/0001209191-20-033322-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120033323/0001209191-20-033323-index.htm |
| 2020-07-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120040666/0001209191-20-040666-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120040669/0001209191-20-040669-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120040695/0001209191-20-040695-index.htm |
| 2020-08-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120044576/0001209191-20-044576-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120047804/0001209191-20-047804-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1708493/000120919120053596/0001209191-20-053596-index.htm |
| 2018-11-26 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1708493/000128864918000006/0001288649-18-000006-index.htm |
| 2019-02-06 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1708493/000135445719000060/0001354457-19-000060-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459019007819/0001564590-19-007819-index.htm |
| 2019-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1708493/000156459019007829/0001564590-19-007829-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1708493/000156459019017497/0001564590-19-017497-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459019017617/0001564590-19-017617-index.htm |
| 2019-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459019028776/0001564590-19-028776-index.htm |
| 2019-08-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1708493/000156459019028819/0001564590-19-028819-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1708493/000156459019041033/0001564590-19-041033-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459019041034/0001564590-19-041034-index.htm |
| 2019-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459019044008/0001564590-19-044008-index.htm |
| 2019-12-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459019046985/0001564590-19-046985-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459020010466/0001564590-20-010466-index.htm |
| 2020-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1708493/000156459020010479/0001564590-20-010479-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459020021929/0001564590-20-021929-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1708493/000156459020022005/0001564590-20-022005-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459020036816/0001564590-20-036816-index.htm |
| 2020-08-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1708493/000156459020036845/0001564590-20-036845-index.htm |
| 2020-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1708493/000156459020050483/0001564590-20-050483-index.htm |
| 2020-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1708493/000156459020050527/0001564590-20-050527-index.htm |
| 2017-06-06 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1708493/000170849317000001/0001708493-17-000001-index.htm |
| 2019-02-07 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1708493/999999999519000124/9999999995-19-000124-index.htm |
| 2020-04-23 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1708493/999999999520000841/9999999995-20-000841-index.htm |
| 2019-02-08 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1708493/999999999719000165/9999999997-19-000165-index.htm |
Harpoon Therapeutics, Inc (HARP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Harpoon Therapeutics, Inc (HARP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1109%Institutional Ownership: 7995%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-05-03 | Gerald PhD McMahon | President and CEO | Buy | 1,000.00 | 10.53 | 10,530.00 | 1,000.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119027964/0001209191-19-027964-index.htm |
| 2019-06-05 | Gerald PhD McMahon | President and CEO | Buy | 169,462.00 | 0.60 | 101,677.20 | 172,462.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119048821/0001209191-19-048821-index.htm |
| 2020-07-31 | Georgia Erbez | Chief Financial Officer | Buy | 1,817.00 | 10.92 | 19,841.64 | 1,817.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120044576/0001209191-20-044576-index.htm |
| 2019-05-08 | Gerald PhD McMahon | President and CEO | Buy | 1,000.00 | 10.56 | 10,558.70 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119028675/0001209191-19-028675-index.htm |
| 2020-05-28 | Bioscience plc Arix | 10% Share Holder | Sell | 366,591.00 | 21.33 | 7,820,925.71 | 2,193,704.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924320014559/0000899243-20-014559-index.htm |
| 2019-02-12 | New Leaf Ventures III, L.P. | 10% Share Holder | Buy | 214,286.00 | 14.00 | 3,000,004.00 | 2,242,839.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010317/0001209191-19-010317-index.htm |
| 2019-02-12 | RONALD HUNT | Director | Buy | 214,286.00 | 14.00 | 3,000,004.00 | 2,242,839.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010306/0001209191-19-010306-index.htm |
| 2020-05-27 | Bioscience plc Arix | 10% Share Holder | Sell | 12,064.00 | 22.39 | 270,144.33 | 2,560,295.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924320014559/0000899243-20-014559-index.htm |
| 2019-12-17 | Bioscience plc Arix | 10% Share Holder | Sell | 12,476.00 | 16.83 | 209,968.58 | 2,572,359.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319029473/0000899243-19-029473-index.htm |
| 2019-12-17 | Mark Chin | Director | Sell | 12,476.00 | 16.83 | 209,968.58 | 2,572,359.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061059/0001209191-19-061059-index.htm |
| 2019-12-16 | Bioscience plc Arix | 10% Share Holder | Sell | 13,080.00 | 17.02 | 222,680.46 | 2,584,835.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319029473/0000899243-19-029473-index.htm |
| 2019-12-16 | Mark Chin | Director | Sell | 13,080.00 | 17.02 | 222,680.46 | 2,584,835.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061059/0001209191-19-061059-index.htm |
| 2019-12-13 | Bioscience plc Arix | 10% Share Holder | Sell | 11,002.00 | 17.21 | 189,341.12 | 2,597,915.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319029473/0000899243-19-029473-index.htm |
| 2019-12-13 | Mark Chin | Director | Sell | 11,002.00 | 17.21 | 189,341.12 | 2,597,915.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061059/0001209191-19-061059-index.htm |
| 2019-12-10 | Bioscience plc Arix | 10% Share Holder | Sell | 131,696.00 | 16.91 | 2,227,018.87 | 2,608,917.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319028848/0000899243-19-028848-index.htm |
| 2019-12-10 | Mark Chin | Director | Sell | 131,696.00 | 16.91 | 2,227,018.87 | 2,608,917.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059954/0001209191-19-059954-index.htm |
| 2019-12-27 | Patrick Baeuerle | Director | Sell | 1,400.00 | 18.07 | 25,296.60 | 262,136.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119062169/0001209191-19-062169-index.htm |
| 2019-12-27 | Patrick Baeuerle | Director | Sell | 10,417.00 | 16.90 | 176,061.88 | 263,536.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119062169/0001209191-19-062169-index.htm |
| 2019-12-27 | Patrick Baeuerle | Director | Sell | 75,562.00 | 15.81 | 1,194,922.36 | 273,953.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119062169/0001209191-19-062169-index.htm |
| 2019-12-09 | Bioscience plc Arix | 10% Share Holder | Sell | 77,316.00 | 18.12 | 1,400,664.39 | 2,740,613.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319028848/0000899243-19-028848-index.htm |
| 2019-12-09 | Mark Chin | Director | Sell | 77,316.00 | 18.12 | 1,400,664.39 | 2,740,613.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059954/0001209191-19-059954-index.htm |
| 2019-12-09 | Bioscience plc Arix | 10% Share Holder | Sell | 26,438.00 | 18.30 | 483,781.03 | 2,817,929.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319028848/0000899243-19-028848-index.htm |
| 2019-12-09 | Mark Chin | Director | Sell | 26,438.00 | 18.30 | 483,781.03 | 2,817,929.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059954/0001209191-19-059954-index.htm |
| 2019-12-06 | Bioscience plc Arix | 10% Share Holder | Sell | 47,752.00 | 19.15 | 914,221.59 | 2,844,367.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319028848/0000899243-19-028848-index.htm |
| 2019-12-06 | Mark Chin | Director | Sell | 47,752.00 | 19.15 | 914,221.59 | 2,844,367.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059954/0001209191-19-059954-index.htm |
| 2019-02-12 | Bioscience plc Arix | 10% Share Holder | Buy | 428,571.00 | 14.00 | 5,999,994.00 | 2,892,119.00 | https://www.sec.gov/Archives/edgar/data/1708493/000089924319003683/0000899243-19-003683-index.htm |
| 2019-02-12 | Mark Chin | Director | Buy | 428,571.00 | 14.00 | 5,999,994.00 | 2,892,119.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010297/0001209191-19-010297-index.htm |
| 2019-05-14 | Gerald PhD McMahon | President and CEO | Buy | 1,000.00 | 10.16 | 10,157.30 | 3,000.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119030200/0001209191-19-030200-index.htm |
| 2019-02-12 | Oncology Impact Fund L.P. UBS | 10% Share Holder | Sell | 447.00 | 14.00 | 6,258.00 | 3,648,422.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010320/0001209191-19-010320-index.htm |
| 2019-02-12 | Oncology Impact Fund L.P. UBS | 10% Share Holder | Buy | 250,000.00 | 14.00 | 3,500,000.00 | 3,898,422.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010320/0001209191-19-010320-index.htm |
| 2020-08-18 | Georgia Erbez | Chief Financial Officer | Buy | 2,098.00 | 11.60 | 24,336.80 | 3,915.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120047804/0001209191-20-047804-index.htm |
| 2019-02-12 | MPM BioVentures 2014, L.P. | 10% Share Holder | Sell | 1,524.00 | 14.00 | 21,336.00 | 4,274,425.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010312/0001209191-19-010312-index.htm |
| 2019-02-12 | LUKE EVNIN | Director | Buy | 250,000.00 | 14.00 | 3,500,000.00 | 4,524,425.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010288/0001209191-19-010288-index.htm |
| 2019-02-12 | MPM BioVentures 2014, L.P. | 10% Share Holder | Buy | 250,000.00 | 14.00 | 3,500,000.00 | 4,524,425.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010312/0001209191-19-010312-index.htm |
| 2019-10-14 | Natalie Sacks | Chief Medical Officer | Sell | 12,452.00 | 13.27 | 165,280.38 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119053306/0001209191-19-053306-index.htm |
| 2019-10-15 | Natalie Sacks | Chief Medical Officer | Sell | 11,698.00 | 13.21 | 154,481.45 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119053306/0001209191-19-053306-index.htm |
| 2019-11-01 | Natalie Sacks | Chief Medical Officer | Sell | 5,826.00 | 13.17 | 76,701.62 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119055169/0001209191-19-055169-index.htm |
| 2019-11-18 | Natalie Sacks | Chief Medical Officer | Sell | 1,000.00 | 14.00 | 14,000.00 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119057167/0001209191-19-057167-index.htm |
| 2019-12-02 | Natalie Sacks | Chief Medical Officer | Sell | 5,826.00 | 17.98 | 104,751.48 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059085/0001209191-19-059085-index.htm |
| 2019-12-16 | Natalie Sacks | Chief Medical Officer | Sell | 1,521.00 | 17.02 | 25,887.57 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061097/0001209191-19-061097-index.htm |
| 2020-01-02 | Natalie Sacks | Chief Medical Officer | Sell | 5,826.00 | 14.18 | 82,600.45 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120002179/0001209191-20-002179-index.htm |
| 2020-01-16 | Natalie Sacks | Chief Medical Officer | Sell | 1,521.00 | 14.94 | 22,724.96 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120004374/0001209191-20-004374-index.htm |
| 2020-02-03 | Natalie Sacks | Chief Medical Officer | Sell | 5,826.00 | 13.90 | 81,006.45 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120006706/0001209191-20-006706-index.htm |
| 2020-02-18 | Natalie Sacks | Chief Medical Officer | Sell | 1,521.00 | 15.00 | 22,815.00 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120011190/0001209191-20-011190-index.htm |
| 2020-03-02 | Natalie Sacks | Chief Medical Officer | Sell | 5,826.00 | 14.68 | 85,525.68 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120015855/0001209191-20-015855-index.htm |
| 2020-03-16 | Natalie Sacks | Chief Medical Officer | Sell | 1.00 | 12.00 | 12.00 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120020052/0001209191-20-020052-index.htm |
| 2020-03-17 | Natalie Sacks | Chief Medical Officer | Sell | 1,520.00 | 12.00 | 18,240.00 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120020052/0001209191-20-020052-index.htm |
| 2020-04-06 | Natalie Sacks | Chief Medical Officer | Sell | 700.00 | 12.00 | 8,400.98 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120023954/0001209191-20-023954-index.htm |
| 2020-04-07 | Natalie Sacks | Chief Medical Officer | Sell | 570.00 | 12.00 | 6,840.00 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120023954/0001209191-20-023954-index.htm |
| 2020-04-13 | Natalie Sacks | Chief Medical Officer | Sell | 4,556.00 | 12.06 | 54,959.03 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024489/0001209191-20-024489-index.htm |
| 2020-04-16 | Natalie Sacks | Chief Medical Officer | Sell | 500.00 | 12.00 | 6,000.00 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024947/0001209191-20-024947-index.htm |
| 2020-04-17 | Natalie Sacks | Chief Medical Officer | Sell | 1,021.00 | 12.08 | 12,330.11 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024947/0001209191-20-024947-index.htm |
| 2020-05-01 | Natalie Sacks | Chief Medical Officer | Sell | 5,826.00 | 12.07 | 70,301.18 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120027143/0001209191-20-027143-index.htm |
| 2020-05-18 | Natalie Sacks | Chief Medical Officer | Sell | 1,522.00 | 14.77 | 22,478.57 | 45,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120031019/0001209191-20-031019-index.htm |
| 2020-03-16 | Natalie Sacks | Chief Medical Officer | Buy | 1.00 | 2.12 | 2.12 | 45,755.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120020052/0001209191-20-020052-index.htm |
| 2020-04-16 | Natalie Sacks | Chief Medical Officer | Buy | 500.00 | 2.12 | 1,060.00 | 46,254.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024947/0001209191-20-024947-index.htm |
| 2020-04-07 | Natalie Sacks | Chief Medical Officer | Buy | 570.00 | 2.12 | 1,208.40 | 46,324.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120023954/0001209191-20-023954-index.htm |
| 2020-04-06 | Natalie Sacks | Chief Medical Officer | Buy | 700.00 | 2.12 | 1,484.00 | 46,454.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120023954/0001209191-20-023954-index.htm |
| 2019-11-18 | Natalie Sacks | Chief Medical Officer | Sell | 17,252.00 | 13.33 | 229,963.98 | 46,754.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119057167/0001209191-19-057167-index.htm |
| 2020-04-17 | Natalie Sacks | Chief Medical Officer | Buy | 1,021.00 | 2.12 | 2,164.52 | 46,775.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024947/0001209191-20-024947-index.htm |
| 2020-03-17 | Natalie Sacks | Chief Medical Officer | Buy | 1,520.00 | 2.12 | 3,222.40 | 47,274.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120020052/0001209191-20-020052-index.htm |
| 2019-12-16 | Natalie Sacks | Chief Medical Officer | Buy | 1,521.00 | 2.12 | 3,224.52 | 47,275.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119061097/0001209191-19-061097-index.htm |
| 2020-01-16 | Natalie Sacks | Chief Medical Officer | Buy | 1,521.00 | 2.12 | 3,224.52 | 47,275.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120004374/0001209191-20-004374-index.htm |
| 2020-02-18 | Natalie Sacks | Chief Medical Officer | Buy | 1,521.00 | 2.12 | 3,224.52 | 47,275.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120011190/0001209191-20-011190-index.htm |
| 2020-05-18 | Natalie Sacks | Chief Medical Officer | Buy | 1,522.00 | 2.12 | 3,226.64 | 47,276.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120031019/0001209191-20-031019-index.htm |
| 2019-12-04 | Georgia Erbez | Chief Financial Officer | Buy | 47,292.00 | 2.12 | 100,259.04 | 47,292.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059489/0001209191-19-059489-index.htm |
| 2020-04-13 | Natalie Sacks | Chief Medical Officer | Buy | 4,556.00 | 2.12 | 9,658.72 | 50,310.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120024489/0001209191-20-024489-index.htm |
| 2019-11-01 | Natalie Sacks | Chief Medical Officer | Buy | 5,826.00 | 2.12 | 12,351.12 | 51,580.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119055169/0001209191-19-055169-index.htm |
| 2019-12-02 | Natalie Sacks | Chief Medical Officer | Buy | 5,826.00 | 2.12 | 12,351.12 | 51,580.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119059085/0001209191-19-059085-index.htm |
| 2020-01-02 | Natalie Sacks | Chief Medical Officer | Buy | 5,826.00 | 2.12 | 12,351.12 | 51,580.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120002179/0001209191-20-002179-index.htm |
| 2020-02-03 | Natalie Sacks | Chief Medical Officer | Buy | 5,826.00 | 2.12 | 12,351.12 | 51,580.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120006706/0001209191-20-006706-index.htm |
| 2020-03-02 | Natalie Sacks | Chief Medical Officer | Buy | 5,826.00 | 2.12 | 12,351.12 | 51,580.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120015855/0001209191-20-015855-index.htm |
| 2020-05-01 | Natalie Sacks | Chief Medical Officer | Buy | 5,826.00 | 2.12 | 12,351.12 | 51,580.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120027143/0001209191-20-027143-index.htm |
| 2020-01-02 | Holger Wesche | Chief Scientific Officer | Sell | 10,000.00 | 14.40 | 143,987.00 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120002180/0001209191-20-002180-index.htm |
| 2020-04-28 | Holger Wesche | Chief Scientific Officer | Sell | 1,250.00 | 14.05 | 17,565.00 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120026337/0001209191-20-026337-index.htm |
| 2020-05-07 | Holger Wesche | Chief Scientific Officer | Sell | 5,350.00 | 14.13 | 75,575.71 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2020-05-08 | Holger Wesche | Chief Scientific Officer | Sell | 1,000.00 | 14.00 | 14,000.00 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2020-05-11 | Holger Wesche | Chief Scientific Officer | Sell | 1,000.00 | 14.07 | 14,065.10 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2020-05-12 | Holger Wesche | Chief Scientific Officer | Sell | 1,400.00 | 14.09 | 19,719.98 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120029020/0001209191-20-029020-index.htm |
| 2020-07-01 | Holger Wesche | Chief Scientific Officer | Sell | 10,000.00 | 16.20 | 161,989.00 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120040695/0001209191-20-040695-index.htm |
| 2020-10-01 | Holger Wesche | Chief Scientific Officer | Sell | 1,000.00 | 17.03 | 17,029.90 | 52,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120053596/0001209191-20-053596-index.htm |
| 2020-05-08 | Holger Wesche | Chief Scientific Officer | Buy | 1,000.00 | 0.60 | 600.00 | 53,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2020-05-11 | Holger Wesche | Chief Scientific Officer | Buy | 1,000.00 | 0.60 | 600.00 | 53,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2020-10-01 | Holger Wesche | Chief Scientific Officer | Sell | 9,000.00 | 16.19 | 145,707.30 | 53,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120053596/0001209191-20-053596-index.htm |
| 2020-04-28 | Holger Wesche | Chief Scientific Officer | Buy | 1,250.00 | 0.60 | 750.00 | 53,919.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120026337/0001209191-20-026337-index.htm |
| 2020-05-12 | Holger Wesche | Chief Scientific Officer | Buy | 1,400.00 | 0.60 | 840.00 | 54,069.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120029020/0001209191-20-029020-index.htm |
| 2019-10-15 | Natalie Sacks | Chief Medical Officer | Buy | 11,698.00 | 2.12 | 24,799.76 | 57,452.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119053306/0001209191-19-053306-index.htm |
| 2020-05-07 | Holger Wesche | Chief Scientific Officer | Buy | 5,350.00 | 0.60 | 3,210.00 | 58,019.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120028407/0001209191-20-028407-index.htm |
| 2019-10-14 | Natalie Sacks | Chief Medical Officer | Buy | 12,452.00 | 2.12 | 26,398.24 | 58,206.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119053306/0001209191-19-053306-index.htm |
| 2020-01-02 | Holger Wesche | Chief Scientific Officer | Buy | 10,000.00 | 0.60 | 6,000.00 | 62,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120002180/0001209191-20-002180-index.htm |
| 2020-07-01 | Holger Wesche | Chief Scientific Officer | Buy | 10,000.00 | 0.60 | 6,000.00 | 62,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120040695/0001209191-20-040695-index.htm |
| 2020-10-01 | Holger Wesche | Chief Scientific Officer | Buy | 10,000.00 | 0.60 | 6,000.00 | 62,669.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120053596/0001209191-20-053596-index.htm |
| 2019-11-18 | Natalie Sacks | Chief Medical Officer | Buy | 18,252.00 | 2.12 | 38,694.24 | 64,006.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119057167/0001209191-19-057167-index.htm |
| 2020-01-21 | Georgia Erbez | Chief Financial Officer | Buy | 6,700.00 | 14.09 | 94,417.74 | 6,700.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120004581/0001209191-20-004581-index.htm |
| 2019-02-12 | New Leaf Ventures III, L.P. | 10% Share Holder | Buy | 214,285.00 | 14.00 | 2,999,990.00 | 678,566.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010317/0001209191-19-010317-index.htm |
| 2019-02-12 | RONALD HUNT | Director | Buy | 214,285.00 | 14.00 | 2,999,990.00 | 678,566.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010306/0001209191-19-010306-index.htm |
| 2019-02-12 | ANSBERT GADICKE | 10% Share Holder | Sell | 1,971.00 | 14.00 | 27,594.00 | 7,922,847.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010303/0001209191-19-010303-index.htm |
| 2019-02-12 | ANSBERT GADICKE | 10% Share Holder | Buy | 500,000.00 | 14.00 | 7,000,000.00 | 8,422,847.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919119010303/0001209191-19-010303-index.htm |
| 2020-08-19 | Georgia Erbez | Chief Financial Officer | Buy | 5,000.00 | 11.40 | 57,000.00 | 8,915.00 | https://www.sec.gov/Archives/edgar/data/1708493/000120919120047804/0001209191-20-047804-index.htm |